|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||98.45 - 100.63|
|52 Week Range||79.62 - 137.88|
|PE Ratio (TTM)||-23.48|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Approximately 112 million adults have tried cannabis at least once.
Marijuana has been making headlines for some time now as more and more states vote to legalize it. Considering the way the cannabinoids work, it makes sense that the main application for medical marijuana would be for neurological disorders — something GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) was quick to latch on to. GWPH’s main focus is pediatric epilepsy (although it does hope to use its proprietary cannabinoid product platform for a broad range of diseases down the road), a neurological disorder marked by recurrent seizures.
The month of August has been hard one for cannabis drug stocks. After Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE ) reported a pair of disappointing trial results in its Phase 2 STAR 1 and STOP trials, respectively, ...